This review article explores the role of epigenetics in cancer, highlighting the importance of epigenetic dysregulation in various stages of tumor progression. It discusses the mechanisms of DNA methylation, histone modifications (including methylation and acetylation), and RNA modifications, emphasizing their reversible nature and therapeutic potential. The article reviews the development and clinical applications of epigenetic inhibitors, such as DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, and BET family inhibitors, which have shown promise in treating hematologic malignancies and solid tumors. The combination of different epigenetic therapies is also discussed as a strategy to enhance therapeutic efficacy and overcome resistance. The article concludes by emphasizing the importance of multi-omics and artificial intelligence (AI) in identifying epigenetic biomarkers for personalized precision medicine, and the potential of advanced epigenetic therapies in cancer treatment.This review article explores the role of epigenetics in cancer, highlighting the importance of epigenetic dysregulation in various stages of tumor progression. It discusses the mechanisms of DNA methylation, histone modifications (including methylation and acetylation), and RNA modifications, emphasizing their reversible nature and therapeutic potential. The article reviews the development and clinical applications of epigenetic inhibitors, such as DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, and BET family inhibitors, which have shown promise in treating hematologic malignancies and solid tumors. The combination of different epigenetic therapies is also discussed as a strategy to enhance therapeutic efficacy and overcome resistance. The article concludes by emphasizing the importance of multi-omics and artificial intelligence (AI) in identifying epigenetic biomarkers for personalized precision medicine, and the potential of advanced epigenetic therapies in cancer treatment.